Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

The Board of Directors of Wellpoint Care Network announced today that Reggie Newson will be the organization’s next President ...

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...